Literature DB >> 12112902

Pulmonary venous pressure: relationship to pulmonary artery, pulmonary wedge, and left atrial pressure in normal, lightly sedated dogs.

Hari P Chaliki1, David G Hurrell, Rick A Nishimura, Rebekah A Reinke, Christopher P Appleton.   

Abstract

Because pulmonary venous pressure has never been measured, it is unclear whether pulmonary wedge pressure measures left atrial pressure, as commonly assumed, or pressure more upstream in the pulmonary venous or capillary beds. Fluid-filled mean pulmonary artery and pulmonary wedge pressure were compared with pulmonary venous and left atrial pressure obtained with high-fidelity micromanometer catheters in eight lightly sedated dogs over a physiologic range of filling pressures. In all conditions, mean pulmonary wedge pressure was virtually identical (r = 0.99) to mean left atrial pressure (slope = 0.99; intercept = -0.46 mm Hg). At the same time, mean pulmonary venous pressure (17.1 +/- 6.5 mm Hg) was intermediate between mean pulmonary artery pressure (20.2 +/- 6.2 mm Hg) and mean pulmonary wedge pressure (13.3 +/- 6.2 mm Hg; P < 0.0001) or mean left atrial pressure (13.4 +/- 6.3 mm Hg; P < 0.0001). These relationships were maintained over normal and increased pressure ranges. As measured by conventional flow-directed pulmonary catheters, mean pulmonary wedge pressure accurately reflects left atrial pressure in lightly sedated, spontaneously breathing normal dogs. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12112902     DOI: 10.1002/ccd.10203

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  8 in total

1.  Relationship of pulmonary artery wedge pressure to left atrial pressure and pulmonary vascular resistance in preoperative Fontan patients.

Authors:  Frederic J Bernstein; Sarah Badran; Cheryl Takao
Journal:  Pediatr Cardiol       Date:  2011-07-26       Impact factor: 1.655

Review 2.  Implantable devices to monitor patients with heart failure.

Authors:  Nikolaos Karamichalakis; John Parissis; George Bakosis; Vasiliki Bistola; Ignatios Ikonomidis; Antonios Sideris; Gerasimos Filippatos
Journal:  Heart Fail Rev       Date:  2018-11       Impact factor: 4.214

3.  Pulmonary Arterial Hypertension Specific Therapy in Patients with Combined Post- and Precapillary Pulmonary Hypertension.

Authors:  Hassan Alfraidi; Sultan Qanash; Zoheir Bshouty
Journal:  Pulm Med       Date:  2018-03-01

4.  Imatinib relaxes the pulmonary venous bed of guinea pigs.

Authors:  Nina A Maihöfer; Said Suleiman; Daniela Dreymüller; Paul W Manley; Rolf Rossaint; Stefan Uhlig; Christian Martin; Annette D Rieg
Journal:  Respir Res       Date:  2017-02-08

5.  Levosimendan reduces segmental pulmonary vascular resistance in isolated perfused rat lungs and relaxes human pulmonary vessels.

Authors:  Annette Dorothea Rieg; Said Suleiman; Nina Andrea Bünting; Eva Verjans; Jan Spillner; Heike Schnöring; Sebastian Kalverkamp; Thomas Schröder; Saskia von Stillfried; Till Braunschweig; Gereon Schälte; Stefan Uhlig; Christian Martin
Journal:  PLoS One       Date:  2020-05-18       Impact factor: 3.240

6.  Left atrial acceleration factor as a magnetic resonance 4D flow measure of mean pulmonary artery wedge pressure in pulmonary hypertension.

Authors:  Gert Reiter; Gabor Kovacs; Clemens Reiter; Albrecht Schmidt; Michael Fuchsjäger; Horst Olschewski; Ursula Reiter
Journal:  Front Cardiovasc Med       Date:  2022-08-03

Review 7.  Evolution from electrophysiologic to hemodynamic monitoring: the story of left atrial and pulmonary artery pressure monitors.

Authors:  Deirdre M Mooney; Erik Fung; Rahul N Doshi; David M Shavelle
Journal:  Front Physiol       Date:  2015-10-07       Impact factor: 4.566

8.  Milrinone relaxes pulmonary veins in guinea pigs and humans.

Authors:  Annette D Rieg; Said Suleiman; Alberto Perez-Bouza; Till Braunschweig; Jan W Spillner; Thomas Schröder; Eva Verjans; Gereon Schälte; Rolf Rossaint; Stefan Uhlig; Christian Martin
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.